| Status | Acronym | ISRCTN | EudraCT | NCT (clinicaltrials.gov) | DRKS |
|---|---|---|---|---|---|
| Active |
A Multi-center, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients
Purpose / Objectives
Primary Outcome
Protocol according to the master protocol “A Multi-center, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients”
Based on the recently published WHO master protocol, the BIH Clinical Study Center (BIH CSC) has developed a central COVID-19 master protocol to harmonize and speed up initiation of COVID-19 clinical trials. The master protocol is available from CSC or via covid19-researchboard@charite.de .
Diagnosis
- COVID-19 infection
Depending individual clinical trial
Target population
Inclusion criteria
Depending on individual clinical trial
Exclusion criteria
Depending on individual clinical trial
Documents (password protected)
Go to download area (no documents yet)